Biomind Labs Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BMNDF research report →
Price Chart
About the company
Biomind Labs Inc. operates as a biotechnology firm dedicated to advancing innovative pharmaceutical therapies and sophisticated nanotech drug delivery mechanisms, primarily addressing a range of psychiatric and neurological disorders. Among its leading pipeline assets, BMND01 is currently in Phase II clinical trials for treating depression.
- CEO
- Alejandro Antalich
- IPO
- 2021
- Employees
- 5
- HQ
- Vancouver, BC, CA
Get TickerSpark's AI analysis on BMNDF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $33.36M
- P/E
- -22.87
- PEG
- 4.63
- P/S
- 0.00
- P/B
- -17.54
- EV/EBITDA
- -24.81
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 83.30%
- ROIC
- 128.74%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-2,269+73.3%
- Op Income
- $-861,418
- Net Income
- $-865,298-232.2%
- EPS
- $-0.01-226.5%
- OCF Growth
- +80.6%
- FCF Growth
- +80.6%
- 52W High
- $0.80
- 52W Low
- $0.01
- 50D MA
- $0.19
- 200D MA
- $0.11
- Beta
- 7.28
- RSI (14)
- 62
- Avg Volume
- 4.06K
No earnings-call transcripts are available for BMNDF yet.
- Free Float
- 63.7%
- Shares Outstanding
- 77.57M
- Float Shares
- 49.41M
Our BMNDF coverage
Recent articles, reports, and earnings notes.
No research on BMNDF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BMNDF report →Biomind Labs Announces Listing on the Canadian Securities Exchange and the Delisting From the Cboe Canada
accessnewswire.com · Aug 6
Biomind Labs Applauds Landmark Executive Order Accelerating Psychedelic Research and Access in The United States
accessnewswire.com · Apr 20
Biomind Labs Announces CAD $2.52 Million Private Placement Financing
accessnewswire.com · Jan 27
Biomind Labs Accelerates FDA Pathway for 5-MEO-DMT Candidate BMND08 with Proprietary Nano-Formulation as Patent Observations Are Successfully Withstood
accessnewswire.com · Dec 3
Biomind Labs Announces Revocation of Cease Trade Order
accessnewswire.com · Nov 25
Biomind Labs Announces Filing of Continuous Disclosure Documents and Appointment of Scott Ackerman to the Board
accessnewswire.com · Nov 18
Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies
accesswire.com · Nov 20
Biomind Labs To Redefine Obesity Treatment With Its New BMND06 Candidate Targeting Neurological Pathways
accesswire.com · Jul 18
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.